The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Saccade/antisaccade latency difference between social and non-social stimuli after oral vasopressin administration
研究概览
简要总结
The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
详细描述
Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. Initial studies have employed intranasal AVP during a socio-emotional eye tracking paradigm and reported effects on both, top-down as well as bottom-up control. Within this context the present study aims to validate the effects of orally administered AVP on top-down and bottom-up attentional control towards socio-affective stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a saccade/anti-saccade task 45 minutes after administration. The task paradigm will encompass social (happy, angry, fearful, sad and neutral faces) and non-social (oval) stimuli to examine the social and emotion-specific effects of oral vasopressin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.
- •Normal or corrected-normal version
排除标准
- •History of neuropsychiatric diseases.
- •History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
- •History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
- •History of renal diseases, including renal stones or renal failure.
- •History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
- •Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
- •Infections such as COVID-19 or influenza, or unexplained fever.
- •Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
- •History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
- •Blood donation (≤ 1 month prior to administration).
- •Take oral contraceptives or receive hormonal medications in the three months prior to the experiment.
- •Pregnant or breastfeeding.
研究组 & 干预措施
Placebo group
Placebo
干预措施: Placebo (Drug)
Vasopressin group
Vasopressin (20IU)
干预措施: Vasopressin (Drug)
结局指标
主要结局
Saccade/antisaccade latency difference between social and non-social stimuli after oral vasopressin administration
时间窗: 45 minutes - 75 minutes after treatment
Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions.
Error rate of saccade/antisaccade for social versus non-social stimuli after oral vasopressin administration
时间窗: 45 minutes - 75 minutes after treatment
Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions.
次要结局
- Error rate of saccade/antisaccade for different facial emotions after oral vasopressin administration(45 minutes - 75 minutes after treatment)
- Saccade/antisaccade latency for different facial emotions after oral vasopressin administration(45 minutes - 75 minutes after treatment)
研究者
Benjamin Becker
Professor
University of Electronic Science and Technology of China